ResearcherHarvard UniversityActive in the last 2 years

Yu‐Ze Luan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2098-7183; OpenAlex author ID A5040551993. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

The Therapeutic Role of NPS-1034 in Pancreatic Ductal Adenocarcinoma as Monotherapy and in Combination with Chemotherapy. Co-author DOI 10.3390/ijms25136919 ↗
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adeno… Co-author DOI 10.1097/mpa.0000000000002125 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wen‐Wei Sung · 1 shared paper, 2024 · strength 0.26
- Paper The Therapeutic Role of NPS-1034 in Pancreatic Ductal Adenocarcinoma as Monotherapy and in Combination with Chemotherap… DOI 10.3390/ijms25136919 ↗
Ming‐Chang Tsai · 1 shared paper, 2024 · strength 0.26
- Paper The Therapeutic Role of NPS-1034 in Pancreatic Ductal Adenocarcinoma as Monotherapy and in Combination with Chemotherap… DOI 10.3390/ijms25136919 ↗
Chi‐Chih Wang · 1 shared paper, 2024 · strength 0.26
- Paper The Therapeutic Role of NPS-1034 in Pancreatic Ductal Adenocarcinoma as Monotherapy and in Combination with Chemotherap… DOI 10.3390/ijms25136919 ↗
Brian Shiian Chen · 1 shared paper, 2022 · strength 0.15
- Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125 ↗
Cho‐Han Chiang · 1 shared paper, 2022 · strength 0.15
- Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125 ↗
Cheng‐Ming Peng · 1 shared paper, 2022 · strength 0.15
- Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125 ↗
Kevin Sheng‐Kai Ma · 1 shared paper, 2022 · strength 0.15
- Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.